How to keep a baby alive with a single dose of an experimental drug

A new drug that may be able to save the lives of babies born with brain tumors has been tested in the UK.

The treatment is in the early stages and doctors are hopeful it can be used in a clinical trial soon.

But the potential benefits are huge.

READ MORE: Doctors test experimental cancer drug that can save babies born without brain tumors article More than 3,000 babies born in Britain have brain tumors, and while many of the children were given the treatment as part of routine surgery, there is no guarantee the drugs would work.

That’s because the drug can cause irreversible brain damage.

“If we can treat these babies with this new drug, it’s going to save their lives,” said Dr. George Fagan, the head of a medical team that is developing the drug, called Zaleplase, in a phone interview with The Globe and Mail.

“There’s nothing that would stop it from working.

It’s a real game changer.”

Fagan is the first Canadian physician to test Zalelase in a human trial.

He is working with researchers at the University of Bristol in the United Kingdom, which is also planning to use the drug in a trial later this year.

Zaleoplase is a compound that can be made from a synthetic peptide that is naturally found in the human body.

The compound, called a peptide, binds to the same receptors found in cells.

The cells can then send signals to the brain to activate the cells that make the drug.

That triggers a process in which the drug gets absorbed into the brain.

The drug works on the same mechanism as Zaleolase, and works to prevent the growth of brain tumors that were caused by another kind of cancer called neuroblastoma.

The drug can also shrink the tumors in a way that mimics the effects of chemotherapy.

Zalesplase also works by binding to different receptors in the brain, and by helping the tumor cells to turn on a specific protein.

That way, the tumor stays under control and the drugs don’t kill the cells.

This treatment is being developed in conjunction with the Royal Free Hospital in London, where Dr. David Marder is the chief medical officer.

In the UK, it was the first time Zalellase has been used to treat brain tumors in children, and the team hopes to see the drug being used in about 50 children.

The trial will test whether the drug works in people with normal levels of the brain tumors.

But for now, there are no plans to use it to treat patients with brain cancer, since it can cause permanent damage to the immune system.

The most common side effects from Zalelyase are mild nausea and headaches.

Zalapedia: The top ten health problems of 2017.

More health stories from around the world: http://bit.ly/2nfK1sE